Antisense Therapeutics’ Phase II Trials Show Promise for New Muscular Dystrophy Drug
Duchenne’s Muscular Dystrophy (DMD) is a devastating generic muscular wasting disorder with a 100% fatality rate . At
News
Antisense Therapeutics
Webcast
Antisense Therapeutics Investor Briefing – 18 November
Antisense Therapeutics (ASX: ANP) is an Australian biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets
Webcast
The Insider – 18 November
This week we were joined by the CEOs of exciting ASX listed businesses, who gave valuable insight to